Castleark Management LLC Invests $8.83 Million in Elanco Animal Health Incorporated $ELAN

Castleark Management LLC purchased a new stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 358,880 shares of the company’s stock, valued at approximately $8,832,000. Castleark Management LLC owned 0.07% of Elanco Animal Health at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new stake in shares of Elanco Animal Health during the second quarter worth approximately $1,202,198,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Elanco Animal Health during the 2nd quarter valued at about $205,636,000. UBS Group AG grew its stake in shares of Elanco Animal Health by 56.7% in the 3rd quarter. UBS Group AG now owns 16,468,148 shares of the company’s stock valued at $331,669,000 after buying an additional 5,961,457 shares in the last quarter. Sei Investments Co. grew its stake in shares of Elanco Animal Health by 737.5% in the 1st quarter. Sei Investments Co. now owns 5,650,393 shares of the company’s stock valued at $135,214,000 after buying an additional 4,975,721 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. increased its holdings in Elanco Animal Health by 11.8% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 35,227,418 shares of the company’s stock worth $797,197,000 after buying an additional 3,717,404 shares during the last quarter. Institutional investors and hedge funds own 97.48% of the company’s stock.

Insider Buying and Selling

In related news, Director Paul Herendeen purchased 10,000 shares of Elanco Animal Health stock in a transaction on Friday, August 7th. The stock was purchased at an average cost of $23.68 per share, with a total value of $236,800.00. Following the acquisition, the director directly owned 111,687 shares in the company, valued at approximately $2,644,748.16. This trade represents a 9.83% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Robert M. Vanhimbergen acquired 4,200 shares of the company’s stock in a transaction dated Friday, August 7th. The shares were bought at an average price of $23.08 per share, for a total transaction of $96,936.00. Following the acquisition, the chief financial officer owned 137,516 shares in the company, valued at approximately $3,173,869.28. This trade represents a 3.15% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased 63,198 shares of company stock valued at $1,473,109 in the last ninety days. Company insiders own 1.14% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the stock. KeyCorp increased their price target on shares of Elanco Animal Health from $29.00 to $30.00 and gave the stock an “overweight” rating in a research note on Thursday, August 6th. Morgan Stanley lifted their price objective on shares of Elanco Animal Health from $23.00 to $26.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 22nd. Weiss Ratings cut shares of Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a report on Thursday, August 20th. Piper Sandler reissued an “overweight” rating on shares of Elanco Animal Health in a research report on Monday, June 29th. Finally, TD Cowen raised their target price on Elanco Animal Health from $31.00 to $32.00 and gave the company a “buy” rating in a report on Thursday, June 18th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Elanco Animal Health currently has a consensus rating of “Moderate Buy” and a consensus target price of $29.09.

Elanco Animal Health Stock Up 2.8%

Elanco Animal Health stock opened at $25.11 on Wednesday. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.05 and a quick ratio of 1.10. Elanco Animal Health Incorporated has a fifty-two week low of $17.11 and a fifty-two week high of $27.98. The firm has a fifty day moving average price of $24.58 and a two-hundred day moving average price of $24.01. The firm has a market cap of $12.55 billion, a price-to-earnings ratio of -61.25, a P/E/G ratio of 1.46 and a beta of 1.67.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $0.34 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.07. The business had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.31 billion. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%.The firm’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same period in the previous year, the company posted $0.26 earnings per share. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. As a group, analysts forecast that Elanco Animal Health Incorporated will post 1.12 earnings per share for the current year.

Elanco Animal Health Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.